8-K: Gyre Therapeutics Reports Q2 2026 Results, Affirms Guidance

Gyre Therapeutics announced its second quarter 2026 financial results, reporting $29.1 million in revenue and affirming full-year revenue guidance, while also detailing progress on its pipeline and the acquisition of Cullgen.

Summary

• Gyre Therapeutics reported Q2 2026 revenue of $29.1 million, a slight decrease from $29.7 million in Q2 2025.
• The company affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million.
• Net loss for Q2 2026 was $14.3 million, compared to a net loss of $2.2 million in Q2 2025.
• The acquisition of Cullgen Inc. closed in May 2026 for approximately $300 million in an all-stock transaction.
• The NDA for F351 (hydronidone) for CHB-induced liver fibrosis was accepted by China's CDE in May 2026.
• ETUARYTM sales increased to $28.0 million in Q2 2026 from $23.5 million in Q2 2025.
• Research and development expenses significantly increased to $19.1 million in Q2 2026 from $8.4 million in Q2 2025, largely due to F351 Phase 3C expenses and a milestone payment to GNI Group Ltd.
• As of June 30, 2026, the company had $103.2 million in cash, cash equivalents, and deposits.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, balancing significant R&D investment and strategic acquisitions with a revenue dip and increased net loss.

Positives

• Affirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million.
• ETUARYTM sales grew to $28.0 million in Q2 2026, up from $23.5 million in Q2 2025.
• The acquisition of Cullgen Inc. was completed, adding a robust degrader pipeline and executive team.
• The NDA for F351 (hydronidone) for CHB-induced liver fibrosis was accepted by China's NMPA.
• The company's cash position remains substantial at $103.2 million as of June 30, 2026.
• Initiated an adaptive Phase 2/3 clinical trial for pirfenidone in oncology-related pulmonary complications.

Negatives

• Total revenue decreased by 2% to $29.1 million in Q2 2026 compared to $29.7 million in Q2 2025.
• Net loss widened significantly to $14.3 million in Q2 2026 from $2.2 million in Q2 2025.
• Sales for EtorelTM decreased to $0.3 million in Q2 2026 from $1.6 million in Q2 2025.
• Sales for ContivaTM decreased to $0.9 million in Q2 2026 from $1.5 million in Q2 2025.
• Research and development expenses more than doubled to $19.1 million in Q2 2026 from $8.4 million in Q2 2025.
• Total cash decreased by 11% to $103.2 million as of June 30, 2026, from $116.1 million as of December 31, 2025.

Risks

• The combined company may not be able to successfully integrate the businesses and realize the expected benefits of the acquisition in a timely manner or at all.
• Uncertainties associated with product candidates, clinical development, and regulatory approval, including potential delays.
• Risks related to the inability to obtain sufficient additional capital to advance product candidates.
• Potential failure to realize value from product candidates and pre-clinical programs.
• Risks associated with the possible failure to realize certain anticipated benefits of the acquisition.
• Unexpected costs, charges, or expenses resulting from the acquisition.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the acquisition.

Future Outlook

The company affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million. Gyre expects to submit IND applications for two additional Cullgen degrader assets in Q1 2027.

Management Comments

• I am very pleased with Gyre's progress over this last quarter, the highlights of which include the acquisition of Cullgen with its robust degrader pipeline and strong executive team, the NMPA acceptance of an NDA for F351 for CHB liver fibrosis, Gyre's second major product candidate after ETUARYTM, and increased sales from our Gyre Pharmaceuticals division, which demonstrates our commercialization capabilities.
• Following the close of our acquisition of Cullgen, we gained a portfolio of targeted protein degraders and degrader-antibody conjugates, while also expanding our pipeline into cancer, inflammatory diseases, cancer pain and solid tumors. We now have a full-spectrum pipeline consisting of clinical and IND-enabling assets to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases, plus a next-generation TPD/DAC platform to complement our legacy, commercial-stage fibrosis platform. We believe the latter provides long-term upside, especially with our China-based innovation capabilities driving cost efficiencies for early-stage development.

Industry Context

StockSavvy.ai notes that Gyre Therapeutics is operating in the competitive biopharmaceutical sector, with a focus on fibrosis and inflammatory diseases. The acquisition of Cullgen positions the company to leverage emerging targeted protein degrader technology, a growing area in drug discovery, while continuing to commercialize existing products in China.

Management Changes

Related Party Transactions

• The acquisition of Cullgen Inc. was an all-stock transaction valued at approximately $300 million, with Cullgen becoming a wholly owned subsidiary. Upon closing, Cullgen's former CEO, Dr. Ying Luo, became President and CEO of Gyre. Yue Xiong (former CSO of Cullgen) became CSO of Gyre, and Thomas Eastling (former CFO of Cullgen) became CFO of Gyre. Ping Zhang was named Chairman.
• The transaction was accounted for as a transaction between entities under common control, with financial statements retrospectively recast.

Stakeholder Impact

• Shareholders: The acquisition of Cullgen expands the pipeline and potential for future growth, but also comes with increased R&D expenses and a wider net loss in the short term. The affirmation of full-year guidance may provide some confidence.
• Employees: The combined company has approximately 740 employees, indicating potential for integration and restructuring impacts.
• Creditors: The company's cash position of $103.2 million provides a buffer, but increased operating expenses and net losses will require careful financial management.

Next Steps

• Continue development of F351 for CHB-induced liver fibrosis in China.
• Analyze China Phase 3 study results and new pre-clinical results for F351 to determine regulatory path for MASH fibrosis Phase 2 studies in the US.
• Plan a Phase 2 study for CG001419 in cancer-induced bone pain.
• Continue Phase 1 trial of CG001419 in China for solid tumors.
• Continue Phase 1 dose-escalation trial of CG009301 in China for high-risk hematologic malignancies.
• Submit IND applications in the US and/or China in Q1 2027 for CG923308 and CG620953.
• Continue development of degrader antibody conjugates (DACs).

Key Dates

Recommendation

The company is making significant strategic investments through the Cullgen acquisition and pipeline development, which is positive for long-term growth. However, the decrease in revenue, widening net loss, and increased R&D expenses in the current quarter warrant a cautious 'hold' stance until the benefits of these investments become clearer and revenue trends stabilize.

Keywords

biopharmaceutical, fibrosis, liver fibrosis, pulmonary fibrosis, drug development, clinical trials, China, acquisition